Endoscopy
DOI: 10.1055/a-2387-9170
Innovations and brief communications

Use of peroral cholangiopancreatoscopy-assisted endoscopic mucosal resection for biliopancreatic intraductal lesions

Wengang Zhang
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Yaqi Zhai
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Bozong Shao
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Jiafeng Wang
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Qingzhen Wu
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
Ningli Chai
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
,
1   Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
› Institutsangaben
Gefördert durch: Chinese PLA General Hospital Young Independent Innovation Science Fund 22QNFC072

Clinical Trial: Registration number (trial ID): ChiCTR2200063675, Trial registry: Chinese Clinical Trial Registry (http://www.chictr.org/), Type of Study: Prospective study

Abstract

Background This study aimed to assess the feasibility and safety of performing cholangiopancreatoscopy-assisted endoscopic mucosal resection (CA-EMR) for biliopancreatic intraductal lesions.

Methods Special electrocautery snares and injection needles that can pass through the working channel of a single-operator cholangiopancreatoscope were developed. Between November 2023 and April 2024, we performed CA-EMR for two patients with gallbladder polyps, one patient with a neoplastic lesion in the common bile duct (CBD), and one patient with a neoplastic lesion in the main pancreatic duct. The technical success rate and adverse events were recorded.

Results All four CA-EMR procedures were performed successfully. Postoperative pathology revealed inflammatory gallbladder polyps in two patients, low grade intraepithelial neoplasia of the CBD in one patient, and intraductal papillary mucinous neoplasm (IPMN) in one patient. The patient with IPMN experienced mild postoperative pancreatitis and recovered after conservative treatment. No adverse events were encountered in the other three CA-EMR procedures.

Conclusion This study preliminarily confirmed the feasibility and safety of CA-EMR for treating biliopancreatic intraductal lesions.

Supplementary Material



Publikationsverlauf

Eingereicht: 01. Mai 2024

Angenommen nach Revision: 14. August 2024

Accepted Manuscript online:
14. August 2024

Artikel online veröffentlicht:
18. Oktober 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany